Melanotan I (Afamelanotide) — Indexed Studies

Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

Seidl-Philipp M, Schratter H, Auer J et al.

Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.

Shetty N, Quiñonez RL, Ceresnie MS et al.

Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report.

Peshin S, Takrori E, Khan KS et al.

From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria.

Minder AE, Barman-Aksözen J

New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective.

Dechant C, Wäscher S, Granata F et al.

Letter to the Editor - Qualitative evidence submitted by patients to NICE: need for more quality or unrealistic and unfair requirements?

Falchetto R, Barman-Aksözen J

Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis.

DerSarkissian M, Norregaard C, Romdhani H et al.

A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic in a tertiary referral centre.

Lai FY, Quigley C, Murray G et al.

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).

Homey B, Schelonke K, Schlegel CM et al.

When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome-18 deletion.

Rovaris S, La Rosa G, Mezzana S et al.

Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.

Rhodes LE

A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.

Jafarzadeh A, Pour Mohammad A, Khosravi M et al.

Erythropoietic protoporphyria and afamelanotide: a patient's perspective.

O'Reilly M, McGuire VA, Dawe RS

A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.

Stanislaus V, Kam A, Murphy L et al.

Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study.

Barman-Aksözen J, Minder AE, Granata F et al.

Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study.

Ceresnie MS, Mohney L, Ko D et al.

Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study.

Wensink D, Wagenmakers MAEM, Qi H et al.

Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.

Minder AE, Barman-Aksoezen J, Schmid M et al.

Liver involvement in patients with erythropoietic protoporphyria.

Wensink D, Coenen S, Wilson JHP et al.

Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain-a patient-reported outcome efficacy measure.

Wensink D, Langendonk JG, Overbey JR et al.

Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.

Arisi M, Rossi M, Rovati C et al.

Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.

Barman-Aksözen J, Nydegger M, Schneider-Yin X et al.

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.

Wensink D, Wagenmakers MAEM, Barman-Aksözen J et al.

Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.

Toh JJH, Chuah SY, Jhingan A et al.

Patients with porphyria bask in sunlight of FDA approval.

Ratner M

Afamelanotide for Erythropoietic Protoporphyria.

Langendonk JG, Balwani M, Anderson KE et al.

Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.

Biolcati G, Marchesini E, Sorge F et al.

Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.

Lengweiler S, Kreim S, Barman-Aksözen J et al.

Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.

Lim HW, Grimes PE, Agbai O et al.

Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease.

Biolcati G, Aurizi C, Barbieri L et al.

A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.

Spichty R, Balimann M, Barman J et al.

Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris.

Böhm M, Ehrchen J, Luger TA

Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis.

von Bartenwerffer W, Siebenhaar G, Hunzelmann N

Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH.

Haylett AK, Nie Z, Brownrigg M et al.

Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal.

Minder EI, Schneider-Yin X, Minder CE

Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.

Harms JH, Lautenschlager S, Minder CE et al.

Biodegradable polyurethane nerve conduits functionalized with NDP-MSH-loaded self-assembling peptide hydrogels for peripheral nerve regeneration.

Li J, Wang J, Long X et al.

Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.

Chawathe A, Sharma N

Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS).

Nkwanyana N, Kumar A, Chakraborty A et al.

Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective.

Dawe RS, Kerr A, Eadie E et al.

Discovery of MT-7117 (Dersimelagon Phosphoric Acid): A Novel, Potent, Selective, and Nonpeptidic Orally Available Melanocortin 1 Receptor Agonist.

Sato A, Morokuma K, Adachi T et al.

Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation.

Mittapelly N, Djehizian A, Telaprolu KC et al.

The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria.

Kluijver LG, Wagenmakers MAEM, Wilson JHP et al.

Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs).

Weirath NA, Haskell-Luevano C

Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.

Suzuki S, Kitanaka C, Okada M

Melanocortin-receptor 4 activation modulates proliferation and differentiation of rat postnatal hippocampal neural precursor cells.

Carniglia L, Turati J, Saba J et al.

Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.

Leaf RK, Naik H, Jiang PY et al.

Quality of life in children with erythropoietic protoporphyria: a case-control study.

Kluijver LG, Wensink D, Wagenmakers MAEM et al.

Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England.

Barman-Aksözen J, Hentschel N, Pettersson M et al.

Polysorbate 80 coated chitosan nanoparticles for delivery of α-melanocyte stimulating hormone analog (NDP-MSH) to the brain reverse cognitive impairment related to neuroinflammation produced by a high-fat diet (HFD).

Herrera G, Scimonelli T, Lasaga M et al.